RankAlpha logo
Back to Rankings

TEVA

Teva Pharmaceutical IndustriesA
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The strongest bull argument is that Q1 2026 showed branded growth carrying the model: AUSTEDO, AJOVY, and UZEDY collectively grew 41% in local currency, 2026 revenue guidance was maintained, and Teva reiterated 2027 margin and savings ambitions while layering in additional neuroscience optionality through Emalex. [#SEC-8K-2026-04-29]
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Commercial execution risk remains elevated because higher selling and marketing expense was needed to support key innovative products, so revenue growth must continue to justify the spend. [#SEC-8K-2026-04-29]
Momentum
100
Value
64
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $39.80 · Bull $44.00 · Bear $28.00Analysis 2026-06-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-27

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $48.09
Why
Momentum100 · Δ7d -0.2
Value64 · Δ7d +0.2
Sentiment53 · Δ7d +2.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta +0.2.

Contradictions & invalidation

  • • Commercial execution risk remains elevated because higher selling and marketing expense was needed to support key innovative products, so revenue growth must continue to justify the spend. [#SEC-8K-2026-04-29]
  • • Emalex adds integration, approval, and margin-risk complexity; Teva explicitly said the deal is expected to be near-term margin dilutive and is still subject to regulatory approvals. [#SEC-8K-2026-04-29]
  • • The bear case is that generic erosion, especially lenalidomide pressure, can keep offsetting branded momentum, while Emalex adds execution and near-term dilution risk before ecopipam contributes revenue; the company is improving, but the thesis still depends on several pipeline and launch milestones landing on time.

Catalyst clock

2026-06-30

Olanzapine LAI regulatory progress could sharpen the late-2026 launch setup

Lead driver: Value · See fundamentals
Momentum
100
8% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.2
Value
64
47% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.6
Sentiment
53
45% active weight
Current posture
7d trendImproving
Δ7d
+2.0
Δ21d
-9.4
Why this grade

Composite grade A. Momentum 99.7 / Value 64.4 / Sentiment 52.6

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-11. Scenario method

B+
Bull case
30%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$39.80
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$46.74B
Beta
0.84
Shares Out
1.17B
P/E (TTM)
49.7
P/S (TTM)
2.08
P/FCF (TTM)
60.34
Rev YoY
-1.4%
EPS YoY
-303.5%
Gross Margin
+52.5%
Op Margin
+18.8%
Net Debt
$13.67B
Current Ratio
0.88
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data